Intra-Cellular Therapies, Inc. 8-K Report: Key Insights from January 8, 2025 Filing

Based on the provided section of the financial report, here are the key insights:

1. Company Information:

• Name: Intra-Cellular Therapies, Inc.
• CIK: 0001567514
• SEC File Number: 001-36274
• State of Incorporation: Delaware (DE)
• IRS Employer Identification Number (EIN): 36-4742850
• Address: 135 Route 202/206 Suite 6, Bedminster, NJ 07921
• Phone: (646) 440-9333

2. Report Type:

• Filing Type: 8-K (This form is used to report major events that shareholders should know about.)

3. Filing Date:

• Date of Filing: January 8, 2025

4. Stock Information:

• Common Stock Ticker: ITCI
• Exchange: NASDAQ

5. Reporting Period:

• Start Date: January 8, 2025
• End Date: January 8, 2025
• The reporting period is for a single day, indicating it might pertain to a specific event or announcement.

6. Additional Notes:

• The information is presented in XBRL (eXtensible Business Reporting Language), which is used for digital financial reporting.

This summary encapsulates essential company and filing details that are relevant for stakeholders or analysts reviewing the 8-K report.